Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Novacare, LLC
WARNING LETTER
•Novacare, LLC•March 22, 2010

FDA WARNING_LETTER - Novacare, LLC - March 22, 2010

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

The FDA conducted an inspection of NovaCare, LLC (TSN Labs, Inc.) from March 8-22, 2010. The inspection revealed that the firm's ingredient (b)(4) and several products marketed as dietary supplements, including "Aziffa," "MONSTER EXCYTE," and "Stiff Nights," contained sulfoaildenafil, an analogue of sildenafil (Viagra's active ingredient).

These products are deemed unapproved new drugs under section 505(a) of the Act [21 U.S.C. § 355(a)] because they are not generally recognized as safe and effective. They are also misbranded drugs under sections 502(f)(1), 502(f)(2), and 502(a) [21 U.S.C. §§ 352(f)(1), 352(f)(2), 352(a)]. The ingredient (b)(4) is also classified as a misbranded drug.

The products' labeling claims, such as "Male Sexual Stimulant" and "INCREASED SEX DRIVE," indicate they are drugs intended to affect body structure/function. Since sulfoaildenafil is a synthetic pharmaceutical ingredient, not a dietary ingredient, these claims do not conform to dietary supplement regulations. Furthermore, the products are considered prescription drugs due to potential harmful

Company
Novacare, LLC
Inspection Date
March 22, 2010
Product Type
Drugs
Office
Denver District Office
Person
  • Thomas Warwick (H.)
Open in Dashboard

ID · db359f7a-71c1-4753-b1f2-09191a3ecbf7

Violation Codes10
21.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 U.S.C. 352(f)(2)21 U.S.C. 352(a)21 U.S.C. 321(g)(1)(D)21 U.S.C. 321(g)(1)(C)21 U.S.C. 321(ff)(1)21 U.S.C. 343(r)(6)21 U.S.C. 331(d)21 U.S.C. 353(b)(1)(A)

Full citation text and observation details available on the Dashboard.

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026, Global Key Solutions All rights reserved.